Amneal Pharmaceuticals Inc

1. 1

   The Transaction Proposal (Proposal 1

   ManagementBoard: FOR

   Approve the Membership Interest Purchase Agreement under which Amneal will acquire 100% of the issued and outstanding membership interests of Kashiv and consummate related transactions.

   More detail

   This proposal seeks shareholder approval of the Membership Interest Purchase Agreement under which Amneal will acquire 100% of Kashiv’s membership interests. Management is seeking approval because the purchase agreement conditions closing on stockholder approval (including a majority of votes cast by Amneal disinterested stockholders) both to honor the parties’ negotiated deal terms and to secure the safe-harbor protections of Section 144 of the DGCL for related-party aspects of the transaction. The contemplated consideration includes $375 million of adjusted cash at closing, 28,942,108 shares of Amneal Class A common stock upfront, up to $350 million of contingent milestone cash payments and royalty payments over a 12-year period, reflecting a mix of upfront and performance-based consideration. The Independent Committee engaged independent financial and legal advisors, obtained a fairness opinion from Goldman Sachs, and unanimously recommended approval; the Amneal Board (excluding certain interested directors) similarly recommends approval. Notable governance context: several Amneal directors and members of the Amneal Group have affiliations or equity interests in Kashiv, which the Independent Committee considered and addressed through its chartered review and the conditioning of the transaction on disinterested stockholder approval. The proxy discloses key risks—regulatory approvals (HSR, Indian approvals), execution and integration risks, potential litigation, dilution, and the possibility the transaction may not close if conditions are unmet. The Independent Committee and Board concluded that strategic rationale (accelerated entry into the biosimilars market, integrated development and manufacturing capabilities, identified synergies and projected financial benefits) outweigh these risks. From an investor evaluation standpoint, the proposal presents potential long-term growth diversification into biosimilars but introduces near-term execution, regulatory and integration risks and immediate dilution from the equity issuance; approval is required for the Transaction to close, and failure to secure the required disinterested stockholder vote will prevent the acquisition.

2. 2

   Stock Issuance Proposal (Proposal 2

   ManagementBoard: FOR

   Approve issuance of 28,942,108 shares of Amneal Class A common stock to the sellers as consideration in connection with the purchase agreement to satisfy Nasdaq Listing Rule 5635(a)(2) and as a condition to closing.

   More detail

   This proposal asks holders to approve the issuance of 28,942,108 Amneal Class A shares to the sellers as part of the negotiated consideration for acquiring Kashiv. Management requires this stockholder authorization to comply with Nasdaq Listing Rule 5635(a)(2) and because the purchase agreement conditions the closing on receipt of the stock issuance approval; absent approval the Transaction cannot close. The issuance will be dilutive to existing Amneal holders and will transfer meaningful economic and voting interest to the sellers; management and the Independent Committee view the share component as an important tool to align incentives and reduce cash outlay at closing. The Independent Committee obtained a fairness opinion from Goldman Sachs regarding the overall consideration package (including cash, equity, milestones and royalties), and both the Independent Committee and the Amneal Board unanimously recommend a vote FOR. Key analyst and investor considerations include the size of the issuance relative to outstanding shares, its impact on voting power and earnings per share, and whether the strategic upside from Kashiv’s pipeline, manufacturing and R&D capabilities offsets the dilution. The proxy explains that if the stock issuance proposal is not approved, the Transaction will not occur, highlighting that this vote is a gating condition and therefore central to the deal’s completion.

3. 3

   Adjournment Proposal (Proposal 3

   ManagementBoard: FOR

   Approve a proposal giving Amneal authority to adjourn or postpone the special meeting from time to time, as determined by the Independent Committee, including to solicit additional votes in favor of the transaction and stock issuance proposals if there are insufficient votes at the meeting.

   More detail

   This proposal seeks authority to adjourn or postpone the special meeting from time to time—as determined in accordance with the purchase agreement by the Independent Committee—so that Amneal may solicit additional proxies if there are insufficient votes to approve the transaction and stock issuance at the scheduled meeting. Management and the Independent Committee argue this is a procedural tool to ensure stockholder deliberation and to allow time to secure the required approvals, and both recommend a vote FOR. The threshold to approve the adjournment proposal is a majority of the shares present in person or represented by proxy at the meeting, and abstentions count as votes AGAINST the adjournment; broker non-votes have no effect. In practice, approval enables Amneal to reconvene later and continue solicitation, which can be important for a complex related-party transaction that conditions closing on stockholder votes. Critics might view an adjournment authority as a mechanism to extend solicitation pressure on dissident holders, but the proxy discloses that Amneal does not intend to call a vote on adjournment if both the transaction and stock issuance have already been approved. The recommendation is supported by the Independent Committee’s view that additional solicitation may be necessary to secure the disinterested stockholder approval required by the purchase agreement.

Upcoming shareholder meetings at Amneal Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Amneal Pharmaceuticals Inc 2026 special meeting?

Amneal Pharmaceuticals Inc (AMRX) holds its 2026 special shareholder meeting on Friday, July 31, 2026.

What is the record date for the Amneal Pharmaceuticals Inc 2026 meeting?

The record date for the Amneal Pharmaceuticals Inc 2026 meeting is Thursday, June 25, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Amneal Pharmaceuticals Inc's 2026 meeting?

The board is presenting 14 director nominees at the Amneal Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Amneal Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Amneal Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.